Health Care • Medical Specialities
$87.41 ▲ +15.89
(+22.22%)
MKT CAP: $3.70B • VOL: 3.56M
52W L $14 52W H $91
CDNA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $379.8M | $333.8M | $280.3M |
| YoY Revenue Growth % | +13.8% | +19.1% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$30.8M | $40.8M | -$203.4M |
| Operating Margin % | -8.1% | 12.2% | -72.5% |
| Net Income (GAAP) | -$21.4M | $52.5M | -$190.3M |
| EBITDA (Normalized) | -$17.1M | $52.8M | -$193.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $42.0M | $38.0M | -$18.4M |
| Capital Expenditures (CapEx) | $17.1M | $15.0M | $12.6M |
| Free Cash Flow (FCF) | $24.9M | $23.0M | -$31.0M |
| FCF Margin % | 6.6% | 6.9% | -11.1% |
| Return on Invested Capital (ROIC %) | -8.5% | 10.2% | -13.1% |
| Cash & Short-Term Equivalents | $65.4M | $114.7M | — |
| Total Debt (Short + Long Term) | $49.6M | $50.7M | $476.2M |
| Total Stockholders' Equity | $303.1M | $378.4M | $976.8M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CDNA.